STOCK TITAN

United Therapeutics Corp - UTHR STOCK NEWS

Welcome to our dedicated news page for United Therapeutics (Ticker: UTHR), a resource for investors and traders seeking the latest updates and insights on United Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect United Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of United Therapeutics's position in the market.

Rhea-AI Summary
United Therapeutics Corporation (Nasdaq: UTHR) announced that Dr. Martine Rothblatt, Chairperson and CEO, will provide an update on the company’s business at the 42nd Annual J.P. Morgan Healthcare Conference. The presentation will be available via live webcast and archived for 30 days. United Therapeutics is a public benefit corporation focused on developing novel pharmaceutical therapies and technologies to expand the availability of transplantable organs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.3%
Tags
conferences
-
Rhea-AI Summary
United Therapeutics Corporation (Nasdaq: UTHR) successfully completes the tender offer to acquire Miromatrix Medical Inc. (Nasdaq: MIRO) for $3.25 per share in cash at closing and an additional $1.75 per share in cash upon the achievement of a clinical development milestone related to mirokidney™ by December 31, 2025. 22,876,102 shares of Miromatrix common stock were validly tendered, representing approximately 83% of the issued and outstanding shares. Merger Sub merged with and into Miromatrix, making it a wholly owned subsidiary of United Therapeutics. Shares of Miromatrix common stock ceased trading on Nasdaq, and United Therapeutics intends to cause such shares to be delisted.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
United Therapeutics Corporation (Nasdaq: UTHR) and Miromatrix Medical Inc. (Nasdaq: MIRO) announced the results of the tender offer by Merger Sub, a United Therapeutics subsidiary, to acquire all outstanding shares of Miromatrix for $3.25 per share in cash at closing and an additional $1.75 per share in cash upon the achievement of a clinical development milestone related to Miromatrix’s mirokidney™ product by December 31, 2025. The tender offer expired with shares representing more than a majority of the issued and outstanding Miromatrix common stock validly tendered and received. The merger is expected to be completed on December 13, 2023, with Miromatrix becoming a wholly owned subsidiary of United Therapeutics and its shares delisted from Nasdaq.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.59%
Tags
none
Rhea-AI Summary
United Therapeutics (Nasdaq: UTHR) has been named on Newsweek’s list of America’s Most Responsible Companies 2024. The company was recognized for its commitment to corporate social responsibility and sustainability, based on publicly available key performance indicators and an independent survey of U.S. residents.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.87%
Tags
none
-
Rhea-AI Summary
United Therapeutics Corporation (Nasdaq: UTHR) reported its financial results for Q3 2023, with total revenues growing 18% YoY to $609.4 million. Net income increased by 12% to $267.6 million. Key product sales, including Tyvaso DPI and nebulized Tyvaso, grew by 225% and decreased by 38%, respectively. The company continues to progress its pipeline with ongoing studies. United Therapeutics aims to achieve a $4 billion annual run rate by mid-decade.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.55%
Tags
-
Rhea-AI Summary
United Therapeutics Corporation has enrolled the first patient in the TETON PPF study, which will evaluate nebulized Tyvaso in adult patients with progressive pulmonary fibrosis (PPF). The study aims to evaluate the impact of nebulized Tyvaso on forced vital capacity (FVC), a key prognostic indicator for PPF. Nebulized Tyvaso is currently approved to treat pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. The TETON PPF study expands the evaluation of nebulized Tyvaso to PPF patients irrespective of whether or not they have pulmonary hypertension.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.01%
Tags
Rhea-AI Summary
United Therapeutics Corporation (Nasdaq: UTHR) announced that Patrick Poisson, EVP, Technical Operations, will provide an overview and update on the company's business at the UBS Biopharma Conference 2023. The session will be held on November 8, 2023, and can be accessed via a live webcast on the United Therapeutics website. An archived version will be available for 180 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.01%
Tags
conferences
-
Rhea-AI Summary
United Therapeutics Corporation (Nasdaq: UTHR) has announced its definitive agreement to acquire Miromatrix Medical Inc. (Nasdaq: MIRO), a life sciences company focused on bioengineered organs. The acquisition will expand United Therapeutics' organ manufacturing programs and address the shortage of transplantable organs. The purchase price is $3.25 per share in cash at closing, with an additional $1.75 per share upon achieving a clinical development milestone. The transaction is expected to close in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
216.35%
Tags
-
Rhea-AI Summary
United Therapeutics Corporation to report Q3 2023 financial results on November 1, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.2%
Tags
conferences earnings
Rhea-AI Summary
United Therapeutics achieves milestones in xenotransplantation programs
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.42%
Tags
none
United Therapeutics Corp

Nasdaq:UTHR

UTHR Rankings

UTHR Stock Data

10.95B
43.37M
1.72%
97.11%
10.39%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Silver Spring

About UTHR

united therapeutics corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. we currently have five approved products on the market, and a long-term mission of providing an unlimited supply of transplantable organs for those who need them! our employees can be found collaborating across the united states, europe and asia. as a group, we are relentless in our pursuit of “medicines for life” and continue to research and develop treatments for cardiovascular and pulmonary diseases, pediatric cancers, and other orphan diseases. #weareunitherians